series-b
Stage
1
Investors
About
ARMGO Pharma is a venture-backed biotech company developing Rycals, novel small-molecule drugs that target ryanodine receptor (RyR) calcium ion channels. Its lead program, ARM210, is being developed for RyR1-related myopathies and for catecholaminergic polymorphic ventricular tachycardia (CPVT).
Explore ARMGO Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.